These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21406348)

  • 21. Synthesis and pharmacological evaluation of 4,4a,5,6-tetrahydro-7,8-disubstituted-benzo[h]cinnolin-3(2H)-ones.
    Pinna GA; Loriga M; Curzu MM; D'Amico M
    Farmaco; 1997 Jan; 52(1):25-8. PubMed ID: 9181677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
    Watanabe N; Kabasawa Y; Takase Y; Matsukura M; Miyazaki K; Ishihara H; Kodama K; Adachi H
    J Med Chem; 1998 Aug; 41(18):3367-72. PubMed ID: 9719589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).
    Nomoto Y; Takai H; Ohno T; Nagashima K; Yao K; Yamada K; Kubo K; Ichimura M; Mihara A; Kase H
    J Med Chem; 1996 Jan; 39(1):297-303. PubMed ID: 8568820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
    Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
    Kim YH; Choi H; Lee J; Hwang IC; Moon SK; Kim SJ; Lee HW; Im DS; Lee SS; Ahn SK; Kim SW; Han CK; Yoon JH; Lee KJ; Choi NS
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6279-82. PubMed ID: 18976905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.
    Gouault N; Martin-Chouly CA; Lugnier C; Cupif JF; Tonnelier A; Feger F; Lagente V; David M
    J Pharm Pharmacol; 2004 Aug; 56(8):1029-37. PubMed ID: 15285848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tricyclic theophylline derivatives with high water-solubility: structure-activity relationships at adenosine receptors, phosphodiesterases, and benzodiazepine binding sites.
    Geis U; Grahner B; Pawłowski M; Drabczynska A; Gorczyca M; Müller CE
    Pharmazie; 1995 May; 50(5):333-6. PubMed ID: 7604066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.
    Roma G; Di Braccio M; Grossi G; Piras D; Leoncini G; Bruzzese D; Signorello MG; Fossa P; Mosti L
    J Med Chem; 2007 Jun; 50(12):2886-95. PubMed ID: 17500510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors.
    Castaño T; Wang H; Campillo NE; Ballester S; González-García C; Hernández J; Pérez C; Cuenca J; Pérez-Castillo A; Martínez A; Huertas O; Gelpí JL; Luque FJ; Ke H; Gil C
    ChemMedChem; 2009 May; 4(5):866-76. PubMed ID: 19350606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
    Crespo MI; Pagès L; Vega A; Segarra V; López M; Doménech T; Miralpeix M; Beleta J; Ryder H; Palacios JM
    J Med Chem; 1998 Oct; 41(21):4021-35. PubMed ID: 9767640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.
    Storelli S; Verdijk P; Verzijl D; Timmerman H; van de Stolpe AC; Tensen CP; Smit MJ; De Esch IJ; Leurs R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2910-3. PubMed ID: 15911279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro.
    Shimoyama M; Kawai M; Nasu S; Shioji K; Hoshi Y
    Physiol Chem Phys; 1975; 7(2):125-32. PubMed ID: 239431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-(beta-Arylethylamino)- and 4-(beta-arylethylamino)quinazolines as phosphodiesterase inhibitors.
    Millen J; Riley TN; Waters IW; Hamrick ME
    J Med Chem; 1985 Jan; 28(1):12-7. PubMed ID: 3965705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
    Alagarsamy V; Rupeshkumar M; Kavitha K; Meena S; Shankar D; Siddiqui AA; Rajesh R
    Eur J Med Chem; 2008 Nov; 43(11):2331-7. PubMed ID: 18031870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and pharmacological investigation of novel 4-(3-ethylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a] quinazolin-5-ones as a new class of H1-antihistaminic agents.
    Alagarsamy V; Kavitha K; Rupeshkumar M; Solomon VR; Kumar J; Kumar DS; Sharma HK
    Acta Pharm; 2009 Mar; 59(1):97-106. PubMed ID: 19304562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis, antitubercular and anticancer activities of substituted furyl-quinazolin-3(4H)-ones.
    Raghavendra NM; Thampi P; Gurubasavarajaswamy PM; Sriram D
    Arch Pharm (Weinheim); 2007 Dec; 340(12):635-41. PubMed ID: 17994604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.